ASCO23 - LBA3: OS analysis from the ADAURA trial of adjuvant osimertinib in resected EGFR‐mutate...
HTML-код
- Опубликовано: 6 сен 2024
- LBA3: Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‐mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). More info @ www.Oncoletter.ch